Porcine epidemic diarrhea (PED) is a severe gastrointestinal disease in swine caused by the porcine epidemic diarrhea virus (PEDV). Despite the continued use of vaccines, PED outbreaks persist, highlighting the need to review their effectiveness and develop new vaccines. This article reviews existing vaccine technologies for preventing PED and highlights promising technologies that may help control PED virus in the future. The primary method of PED transmission is through fecal-to-oral contact, leading to high mortality rates among newborn piglets. PEDV primarily targets intestinal epithelial cells, causing degeneration, necrosis, and loss of villi, which results in impaired nutrient absorption and symptoms such as vomiting, diarrhea, weight loss, and potential death. PED was initially identified in the United Kingdom in 1971 and quickly spread to Europe and Asia. In 2013, PED emerged in the United States and rapidly spread globally, leading to a global epidemic during 2013–2014. PEDV is a member of the *Alphacoronavirus* genus within the *Coronaviridae* family and is classified into two main genogroups: genogroup 1 (G1) and genogroup 2 (G2). Vaccination strategies for PEDV include live attenuated vaccines (LAVs), inactivated vaccines, subunit vaccines, virus-like particle (VLP) vaccines, viral vector vaccines, and nucleic acid vaccines. LAVs are known for their high immunogenicity but pose safety concerns due to the risk of reversion to virulence. Inactivated vaccines are safe and easy to produce but may compromise immunogenicity. Subunit vaccines offer enhanced safety and consistent antigens but require adjuvants for effectiveness. VLP vaccines, a subset of subunit vaccines, are noninfectious and elicit strong immune responses. Viral vector vaccines, such as adenovirus, vesicular stomatitis virus, and poxvirus, have shown promise in inducing protective immunity. Nucleic acid vaccines, including DNA and mRNA vaccines, offer rapid production and are cost-effective but face challenges in immunogenicity. Despite advancements, the development of effective PED vaccines remains challenging due to the high mutation rates of RNA viruses and the need for mucosal immunity. Next-generation vaccines are expected to address these challenges by providing rapid and effective protection against PEDV.Porcine epidemic diarrhea (PED) is a severe gastrointestinal disease in swine caused by the porcine epidemic diarrhea virus (PEDV). Despite the continued use of vaccines, PED outbreaks persist, highlighting the need to review their effectiveness and develop new vaccines. This article reviews existing vaccine technologies for preventing PED and highlights promising technologies that may help control PED virus in the future. The primary method of PED transmission is through fecal-to-oral contact, leading to high mortality rates among newborn piglets. PEDV primarily targets intestinal epithelial cells, causing degeneration, necrosis, and loss of villi, which results in impaired nutrient absorption and symptoms such as vomiting, diarrhea, weight loss, and potential death. PED was initially identified in the United Kingdom in 1971 and quickly spread to Europe and Asia. In 2013, PED emerged in the United States and rapidly spread globally, leading to a global epidemic during 2013–2014. PEDV is a member of the *Alphacoronavirus* genus within the *Coronaviridae* family and is classified into two main genogroups: genogroup 1 (G1) and genogroup 2 (G2). Vaccination strategies for PEDV include live attenuated vaccines (LAVs), inactivated vaccines, subunit vaccines, virus-like particle (VLP) vaccines, viral vector vaccines, and nucleic acid vaccines. LAVs are known for their high immunogenicity but pose safety concerns due to the risk of reversion to virulence. Inactivated vaccines are safe and easy to produce but may compromise immunogenicity. Subunit vaccines offer enhanced safety and consistent antigens but require adjuvants for effectiveness. VLP vaccines, a subset of subunit vaccines, are noninfectious and elicit strong immune responses. Viral vector vaccines, such as adenovirus, vesicular stomatitis virus, and poxvirus, have shown promise in inducing protective immunity. Nucleic acid vaccines, including DNA and mRNA vaccines, offer rapid production and are cost-effective but face challenges in immunogenicity. Despite advancements, the development of effective PED vaccines remains challenging due to the high mutation rates of RNA viruses and the need for mucosal immunity. Next-generation vaccines are expected to address these challenges by providing rapid and effective protection against PEDV.